Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone
Peter Jenner, José‐Francisco Rocha, Joaquim J. Ferreira, et al.
Expert Review of Neurotherapeutics (2021) Vol. 21, Iss. 9, pp. 1019-1033
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications
Paras Mani Giri, Anurag Banerjee, Arpita Ghosal, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3995-3995
Open Access | Times Cited: 30
Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives
Virendra Kumar Yadav, Seshathiri Dhanasekaran, Nisha Choudhary, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access | Times Cited: 2
COMT Inhibitors in the Management of Parkinson’s Disease
Margherita Fabbri, Joaquim J. Ferreira, Olivier Rascol
CNS Drugs (2022) Vol. 36, Iss. 3, pp. 261-282
Closed Access | Times Cited: 38
Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
Martin Regensburger, Chi Wang Ip, Zacharias Kohl, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 847-861
Open Access | Times Cited: 31
Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach
Gurkaran Singh Baweja, Shankar Gupta, Bhupinder Kumar, et al.
Molecular Diversity (2023) Vol. 28, Iss. 3, pp. 1823-1845
Open Access | Times Cited: 22
Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach
Andrew J. Lees, Eduardo Tolosa, Fabrizio Stocchi, et al.
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 1, pp. 15-24
Open Access | Times Cited: 16
Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson’s Disease
Ling Yi, Eng King Tan, Zhidong Zhou
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4643-4643
Open Access | Times Cited: 5
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, et al.
Movement Disorders (2022) Vol. 37, Iss. 11, pp. 2272-2283
Open Access | Times Cited: 22
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?
András Salamon, Dénes Zádori, László Szpisjak, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 10, pp. 1123-1128
Open Access | Times Cited: 20
Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial
Joaquim J. Ferreira, Olivier Rascol, Fabrizio Stocchi, et al.
European Journal of Neurology (2025) Vol. 32, Iss. 1
Open Access
Opicapone

Cambridge University Press eBooks (2025), pp. 324-332
Closed Access
Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson’s disease: Systematic review and network meta-analysis
Wenshuo Wu, Xiaohui Lu, Liping Zhang, et al.
Clinical Neurology and Neurosurgery (2024) Vol. 239, pp. 108189-108189
Closed Access | Times Cited: 3
DFT and QSAR study of Catechol-O-methyltransferase (COMT) as inhibitors for Parkinson’s disease treatment
Salma Sherif, Ahmed Sameh, Sohaila Mohammed Salah, et al.
Optical and Quantum Electronics (2024) Vol. 56, Iss. 4
Open Access | Times Cited: 2
Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
Diego Santos‐García, Gustavo Fernández‐Pajarín, Juan Manuel Oropesa-Ruiz, et al.
Brain Sciences (2022) Vol. 12, Iss. 3, pp. 383-383
Open Access | Times Cited: 9
DESI-MSI-based technique to unravel spatial distribution of COMT inhibitor Tolcapone
Joana Rebouta, M. Luísa Dória, Filipa Campos, et al.
International Journal of Pharmaceutics (2023) Vol. 633, pp. 122607-122607
Closed Access | Times Cited: 5
Development of Prodrugs for Treatment of Parkinson‘s Disease: New Inorganic Scaffolds for Blood–Brain Barrier Permeation
Veronica Di Battista, Evamarie Hey‐Hawkins
Journal of Pharmaceutical Sciences (2022) Vol. 111, Iss. 5, pp. 1262-1279
Closed Access | Times Cited: 8
The prospective role of mesenchymal stem cells in Parkinson's disease
Pratima Tambe, Vaishali Undale, Avinash Sanap, et al.
Parkinsonism & Related Disorders (2024) Vol. 127, pp. 107087-107087
Closed Access | Times Cited: 1
Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson’s disease: pooled analysis of patient level data from two randomized open-label studies
Joaquim J. Ferreira, Jee‐Young Lee, Hyeo‐Il Ma, et al.
Journal of Neurology (2024) Vol. 271, Iss. 10, pp. 6729-6738
Open Access | Times Cited: 1
Addressing the Ethnicity Gap in Catechol O-Methyl Transferase Inhibitor Trials in Parkinson’s Disease: A Review of Available Global Data
Karolina Popławska-Domaszewicz, Naomi Limbachiya, Mubasher A. Qamar, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 9, pp. 939-939
Open Access | Times Cited: 1
Absorption, metabolism and excretion of opicapone in human healthy volunteers
Ana I. Loureiro, Francisco Rocha, A. Santos, et al.
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 10, pp. 4540-4551
Open Access | Times Cited: 7
Stellenwert der COMT-Hemmer in der Therapie motorischer Fluktuationen
Wolfgang H. Jost, Carsten Buhmann, Joseph Claßen, et al.
Der Nervenarzt (2022) Vol. 93, Iss. 10, pp. 1035-1045
Closed Access | Times Cited: 5
Adverse event profiles of adjuvant treatment with opicapone in Parkinson’s disease: A systematic review and meta-analysis
Luwen Xie, Xiaoyi Qi, Xuan Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 3
The Relationship Between COMT and MAO-B Gene Polymorphisms with Levodopa in Parkinson’s Disease Patients; A Review
Vina Luthfiana Hasna, Ahsanal Kasasiah, Rosario Trijuliamos Manalu, et al.
Deleted Journal (2024) Vol. 10, Iss. 1, pp. 1-10
Open Access
Prodrugs for neurodegenerative diseases
Paolo Guglielmi, Arianna Granese, Daniela Secci, et al.
Elsevier eBooks (2024), pp. 265-284
Closed Access
The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's disease
Raafat Soliman, Nourhan S. Sultan, Hagar Mostafa Lokman, et al.
Elsevier eBooks (2024), pp. 187-201
Closed Access
Page 1 - Next Page

Scroll to top